Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture.
The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture.
Jonathan Goldman, CEO of Abzena, said: “This new integrated offering will provide our partners a de-risked approach to biosimilar development, all the way to clinical development and ultimately to the market.”
Gerrit Hagens, Director at BioXpress Therapeutics, commented: “This partnership allows for a simplification of drug development timelines for the biosimilars market. The BioXpress Therapeutics and Abzena strengths are complementary and this partnership provides a flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”